Delays to surgery following chemoradiotherapy lead to poorer oncologic outcomes in patients with localized pancreatic adenocarcinoma.
Javier A CienfuegosPablo Martí-CruchagaGabriel ZozayaJosé Luis Hernández LizoainFernando Martínez RegueiraFernando PardoJavier RodríguezLeire Arbea MorenoFernando RotellarPublished in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2022)
100 (8.3%) of 120 eligible patients underwent PD: 61 male, median age of 63.7 years. In 71 (71%) patients the median NCRT-TTS was 39 (24-50) days and in 29 (29%) 61 days. There were no differences between the two groups except for CA 19-9 levels, the incidence of cholangitis, ASA score, intraoperative blood transfusions and degree of histopathologic response (all p< 0.001). Median DFS when the NCRT-TTS was less than 50 days was higher than when the interval exceeded 50 days - 51.0 months (95% CI 20.3-81.6) vs 17.0 months (95% CI 10.9-23.0); HR (95% CI 1.08-3.46), p=0.026. Five-year DFS was higher in the subgroup with the NCRT-TTS of less than 50 days compared to the group with an interval of more than 50 days - 43.5% vs 23.65% (HR 1.812 95% CI 1.001-3.280), p= 0.050 Conclusions. An increase in the NCRT-TTS > 50 days is associated with poorer OS and DFS in patients with localized PDAC treated with NCRT and PD.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- prostate cancer
- squamous cell carcinoma
- minimally invasive
- metabolic syndrome
- randomized controlled trial
- clinical trial
- patient reported outcomes
- risk factors
- skeletal muscle
- atrial fibrillation
- locally advanced
- radical prostatectomy